ADORA3
ENSG00000282608
Target class
GPCR
Chromosome
1
Approved drugs
7
Clinical candidates (approved and in development)
10
- Approved drugs
- 7
- Clinical candidates (approved and in development)
- 10
- Chemical probe available
- Yes
- Target name
- ADORA3
- Gene name
- Adenosine A3 receptor
- Gene symbol
- ADORA3
- Protein name
- Adenosine receptor A3
- AD026
- A3AR
- Gene biotype
- Protein coding
- Gene family
- Adenosine receptors|V-set domain containing
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 43
- Highest tissue expression
- 14.82
- Tissue specificity (Gini)
- 0.415
- Tissue specificity (tau)
- 0.821
- KEGG gene identifiers
- hsa:140
- Protein interaction confidence
- 0.9148
- Protein interaction partners
- 5
- R-HSA-417973
- R-HSA-418594
- End position
- 111503633
- Start position
- 111499429
- Chromosome
- 1
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein .
- PubMed 38627384
- PubMed 40825947
- Tissue specificity (tau)
- 0.820576
- Expression inequality (Gini)
- 0.415358
Expression in transcripts per million
- Brain - Spinal cord (cervical c-1)
- 14.82
- Nerve - Tibial
- 8.48
- Adrenal Gland
- 7.99
- Small Intestine - Terminal Ileum
- 6.63
- Brain - Substantia nigra
- 5.75
Expression in transcripts per million
- Brain - Spinal cord (cervical c-1)14.82
- Nerve - Tibial8.48
- Adrenal Gland7.99
- Small Intestine - Terminal Ileum6.63
- Brain - Substantia nigra5.75
- Spleen4.97
- Bladder4.92
- Brain - Hypothalamus4.47
- Cervix - Endocervix4.44
- Artery - Aorta4.16
- Artery - Coronary4.09
- Colon - Transverse3.94
- Lung3.89
- Fallopian Tube3.83
- Adipose - Subcutaneous3.79
- Brain - Hippocampus3.5
- Brain - Amygdala3.49
- Esophagus - Gastroesophageal Junction3.47
- Colon - Sigmoid3.44
- Adipose - Visceral (Omentum)3.43
- Esophagus - Muscularis3.24
- Prostate3.14
- Minor Salivary Gland2.58
- Brain - Caudate (basal ganglia)2.52
- Breast - Mammary Tissue2.48
And 29 more, listed on the interactive page.
- GO:0006954
- GO:0007165
- GO:0007190
- GO:0007193
- GO:0008016
- GO:0008285
- GO:0009611
- GO:0030336
Cellular components
- GO:0005886
Molecular functions
- GO:0001609
angiogenesis
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: angiogenesis
- cardiovascular system
- immune
Evidence sourcedecreased convulsions
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased convulsions
- nervous system
- respiratory
PubMed 28216264interference with the regulation of cell growth (inferred by author)
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: interference with the regulation of cell growth (inferred by author)
- cardiovascular system
- immune
Evidence sourcecell proliferation
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: cell proliferation
- cardiovascular system
- immune
Evidence sourcedecreased locomotor activity
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased locomotor activity
- nervous system
- respiratory
PubMed 28216264increased bronchoconstriction
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased bronchoconstriction
- nervous system
- respiratory
PubMed 28216264increased convulsions
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased convulsions
- nervous system
- respiratory
PubMed 28216264decreased pain
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased pain
- nervous system
- respiratory
PubMed 28216264myocardial ischemia (inferred by author)
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: myocardial ischemia (inferred by author)
- cardiovascular system
- immune
Evidence sourcecell necrosis
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: cell necrosis
- cardiovascular system
- immune
Evidence sourceantiischaemic (cardioprotective)
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: antiischaemic (cardioprotective)
- cardiovascular system
- immune
Evidence sourcehypertension (inferred by author)
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: hypertension (inferred by author)
- cardiovascular system
- immune
Evidence sourceproischemic (cerebral)
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: proischemic (cerebral)
- cardiovascular system
- immune
Evidence sourcehypotension
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: hypotension
- cardiovascular system
- immune
Evidence sourceimmunosuppression
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: immunosuppression
- cardiovascular system
- immune
Evidence sourceproinflammatory effects (inferred by author)
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: proinflammatory effects (inferred by author)
- cardiovascular system
- immune
Evidence source
Related records
Trials (642)
- "Pecos" B-adrenergic and PPAR-G Stimulation Upregulates Lipid Metabolism in Human Subcutaneous Fat
- 12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa
- 12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa
- A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
- A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788
- A Comparison of Nicardipine and Labetalol for Blood Pressure Control in Intensive Care Patients After Hemorrhagic Stroke Brain Surgery
- A Comparison Study of Apadenoson and Adenosine to Treadmill Exercise Stress.
- A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
- A Dental Pain Study Comparing The Analgesic Efficacy Of Ibuprofen/Caffeine
- A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)
- A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI
- A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin
- A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
- A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer
- A Long Term Study to Assess the Safety of Fostamatinib in Patients in Asia With Rheumatoid Arthritis
- A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy
- A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma
- A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1
- A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
- A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy
Drugs (33)
- Adenosine Adenosine receptor agonist
- Aminophylline Adenosine receptor antagonist
- Apadenoson
- Binodenoson
- Caffeine Adenosine receptor antagonist
- Caffeine citrate Adenosine receptor antagonist
- Derenofylline
- Dexniguldipine
- FK453
- Flavone
- Fostamatinib
- GS 6201
- GS-9667
- Istradefylline
- LUF-5981
- LUF-6000
- LUF-6096
- Namodenoson Adenosine A3 receptor agonist
- Nicardipine
- Oxtriphylline Adenosine receptor antagonist